These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34331337)

  • 1. Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine.
    Horak P; Leichsenring J; Goldschmid H; Kreutzfeldt S; Kazdal D; Teleanu V; Endris V; Gieldon L; Allgäuer M; Volckmar AL; Dikow N; Renner M; Kirchner M; Penzel R; Ploeger C; Brandt R; Seker-Cin H; Budczies J; Heilig CE; Neumann O; Schaaf CP; Schirmacher P; Fröhling S; Stenzinger A
    Genes Chromosomes Cancer; 2022 Jun; 61(6):303-313. PubMed ID: 34331337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
    Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical bioinformatics desiderata for molecular tumor boards.
    Pallocca M; Betti M; Baldinelli S; Palombo R; Bucci G; Mazzarella L; Tonon G; Ciliberto G
    Brief Bioinform; 2024 Jul; 25(5):. PubMed ID: 39297878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Variant interpretation in molecular pathology and oncology : An introduction].
    Horak P; Leichsenring J; Kreutzfeldt S; Kazdal D; Teleanu V; Endris V; Volckmar AL; Renner M; Kirchner M; Heilig CE; Neumann O; Schirmacher P; Fröhling S; Stenzinger A
    Pathologe; 2021 Jul; 42(4):369-379. PubMed ID: 33938987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioinformatics workflows for clinical applications in precision oncology.
    Jäger N
    Semin Cancer Biol; 2022 Sep; 84():103-112. PubMed ID: 33476720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
    Knepper TC; Bell GC; Hicks JK; Padron E; Teer JK; Vo TT; Gillis NK; Mason NT; McLeod HL; Walko CM
    Oncologist; 2017 Feb; 22(2):144-151. PubMed ID: 28179575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physician interpretation of genomic test results and treatment selection.
    Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
    Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attention mechanism models for precision medicine.
    Cheng L
    Brief Bioinform; 2024 May; 25(4):. PubMed ID: 38811359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing precision cancer medicine in the genomic era.
    Chen HZ; Bonneville R; Roychowdhury S
    Semin Cancer Biol; 2019 Apr; 55():16-27. PubMed ID: 29857039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variant classification in precision oncology.
    Leichsenring J; Horak P; Kreutzfeldt S; Heining C; Christopoulos P; Volckmar AL; Neumann O; Kirchner M; Ploeger C; Budczies J; Heilig CE; Hutter B; Fröhlich M; Uhrig S; Kazdal D; Allgäuer M; Harms A; Rempel E; Lehmann U; Thomas M; Pfarr N; Azoitei N; Bonzheim I; Marienfeld R; Möller P; Werner M; Fend F; Boerries M; von Bubnoff N; Lassmann S; Longerich T; Bitzer M; Seufferlein T; Malek N; Weichert W; Schirmacher P; Penzel R; Endris V; Brors B; Klauschen F; Glimm H; Fröhling S; Stenzinger A
    Int J Cancer; 2019 Dec; 145(11):2996-3010. PubMed ID: 31008532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automatic Integration of Clinical and Genetic Data Using cBioPortal.
    Brunner M; Mullen L; Jauk F; Oliver J; Cayol F; Minata J; Herrera V; Pavicic W; Luna D; Risk M; Garcia Rivello H; Benitez S
    Stud Health Technol Inform; 2022 Jun; 290():799-803. PubMed ID: 35673128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrated clinical and genomic information system for cancer precision medicine.
    Jang Y; Choi T; Kim J; Park J; Seo J; Kim S; Kwon Y; Lee S; Lee S
    BMC Med Genomics; 2018 Apr; 11(Suppl 2):34. PubMed ID: 29697362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.
    Martin-Romano P; Mezquita L; Hollebecque A; Lacroix L; Rouleau E; Gazzah A; Bahleda R; Planchard D; Varga A; Baldini C; Postel-Vinay S; Friboulet L; Loriot Y; Verlingue L; Geraud A; Camus MN; Nicotra C; Soria JC; André F; Besse B; Massard C; Italiano A
    JCO Precis Oncol; 2022 Oct; 6():e2100484. PubMed ID: 36315916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision Medicine Intelligence - evidence scoring evaluating the clinical actionability of BRAF V600E in multiple non-melanoma solid tumors.
    Crescenzo A
    Drugs Today (Barc); 2016 Jul; 52(7):399-405. PubMed ID: 27540599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
    Perera-Bel J; Hutter B; Heining C; Bleckmann A; Fröhlich M; Fröhling S; Glimm H; Brors B; Beißbarth T
    Genome Med; 2018 Mar; 10(1):18. PubMed ID: 29544535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology.
    Reardon B; Moore ND; Moore NS; Kofman E; AlDubayan SH; Cheung ATM; Conway J; Elmarakeby H; Imamovic A; Kamran SC; Keenan T; Keliher D; Konieczkowski DJ; Liu D; Mouw KW; Park J; Vokes NI; Dietlein F; Van Allen EM
    Nat Cancer; 2021 Oct; 2(10):1102-1112. PubMed ID: 35121878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.
    Chae YK; Pan AP; Davis AA; Patel SP; Carneiro BA; Kurzrock R; Giles FJ
    Mol Cancer Ther; 2017 Dec; 16(12):2645-2655. PubMed ID: 29203694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.
    Ortiz MV; Kobos R; Walsh M; Slotkin EK; Roberts S; Berger MF; Hameed M; Solit D; Ladanyi M; Shukla N; Kentsis A
    Pediatr Blood Cancer; 2016 Aug; 63(8):1368-74. PubMed ID: 27082517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A platform for oncogenomic reporting and interpretation.
    Reisle C; Williamson LM; Pleasance E; Davies A; Pellegrini B; Bleile DW; Mungall KL; Chuah E; Jones MR; Ma Y; Lewis E; Beckie I; Pham D; Matiello Pletz R; Muhammadzadeh A; Pierce BM; Li J; Stevenson R; Wong H; Bailey L; Reisle A; Douglas M; Bonakdar M; Nelson JMT; Grisdale CJ; Krzywinski M; Fisic A; Mitchell T; Renouf DJ; Yip S; Laskin J; Marra MA; Jones SJM
    Nat Commun; 2022 Feb; 13(1):756. PubMed ID: 35140225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Need for Multi-Omics Biomarker Signatures in Precision Medicine.
    Olivier M; Asmis R; Hawkins GA; Howard TD; Cox LA
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.